Delisting risk
Intensity Therapeutics (INTS)
Develops INT230-6, a tumor-injection treatment candidate for solid cancers.
$4.00
Pre-market−0.05 (−1.23%)
At close$4.05(−0.49%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions14 holders · as of Mar 31, 2026 | 5.52% | 180.3K shares | |
| Insiders3 holders · as of Jul 1, 2026 | 3.92% | 127.9K shares | |
| Otherremainder | 90.56% | 2.96M shares |
3.26M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (3.26M in the company's Sep 3, 2026 report, 2.70M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Institutions13F, as of Mar 31, 2026
14 holders · 180.3K shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Kingsbury Capital Investment Advisors LLC | 38.1K | 1.17% | Aug 25, 2026 | |
| Geode Capital Management, LLC | 26.0K | 0.80% | May 15, 2026 | |
| Sapient Capital LLC | 26.0K | 0.80% | Jun 22, 2026 | |
| Nano Cap New Millennium Growth Fund L P | 25.0K | 0.77% | May 15, 2026 | |
| Sentinus, LLC | 23.3K | 0.71% | May 6, 2026 | |
| Vanguard Capital Management LLC | 16.8K | 0.52% | May 15, 2026 | |
| Mesirow Financial Investment Management, Inc. | 14.1K | 0.43% | Apr 21, 2026 | |
| Vanguard Fiduciary Trust Co | 9.1K | 0.28% | May 8, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.